Sarah Severson-Hutchison, MD
Family Medicine · Tucson, AZNPI 1437508553
Payments from drug & device makers
Across 146 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$526
- AbbVie$387
- Abbott$200
- Amgen$172
- GSK$172
- Aimmune Therapeutics, Inc.$91
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,48697%
- Education$653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $526 |
| AbbVie | 22 | $387 |
| Abbott | 9 | $200 |
| Amgen | 10 | $172 |
| GSK | 10 | $172 |
| Aimmune Therapeutics, Inc. | 6 | $91 |
| Lilly USA, LLC | 5 | $87 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| Exact Sciences | 4 | $75 |
| AstraZeneca | 5 | $68 |
| Nestle Healthcare Nutrition Inc. | 5 | $67 |
| Pfizer | 4 | $64 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Corcept Therapeutics | 2 | $56 |
| Novartis | 2 | $45 |
| Merck | 2 | $39 |
| Boehringer Ingelheim | 2 | $36 |
| Johnson & Johnson | 2 | $36 |
| Eisai Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Gilead | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Corium, LLC | 2 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Boston Scientific | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$2,550 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $87,691 |
| EliquisApixaban | 56 | $56,422 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $43,047 |
| JardianceEmpagliflozin | 29 | $38,186 |
| ProliaDenosumab | 19 | $33,472 |
| XareltoRivaroxaban | 25 | $29,361 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $28,964 |
| FarxigaDapagliflozin Propanediol | 18 | $21,049 |
| MounjaroTirzepatide | 17 | $20,445 |
| JanuviaSitagliptin Phosphate | 21 | $18,333 |
| WegovySemaglutide | 11 | $14,796 |
| MyrbetriqMirabegron | 13 | $12,522 |
| GemtesaVibegron | 14 | $12,279 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,904 |
| LivaloPitavastatin Calcium | 14 | $8,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $526 | $102,48780 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $68 | $64,09556 claims |
| PfizerEliquis, Paxlovid | $64 | $57,85282 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $36 | $47,09046 claims |
| AmgenProlia | $172 | $33,47219 claims |
| Johnson & JohnsonXarelto | $36 | $29,36125 claims |
| GSKTrelegy Ellipta | $172 | $28,96426 claims |
| MerckJanuvia, Belsomra | $39 | $25,07134 claims |
| Lilly USA, LLCMounjaro | $87 | $20,44517 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $12,52213 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $13 | $8,08014 claims |
| AbbVieSynthroid | $387 | $2,23624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Dena PetersenTucson$14.7M
- John McGettiganTucson$8.3M
- Kevin PoundsTucson$1.9M
- Thili KulatilakeTucson$1.8M
- Judith BrownTucson$399K
- Hannah LeslieTucson$228K
- Charles MichieliTucson$111K
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.